Associated Papers
Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects.
Bernsen EC et al.
Clinical Pharmacology and Therapeutics, 2025
40331624 (PubMed )
Supplement: CPT-118-438-s002.xlsx › DPYD
PAnno: A pharmacogenomics annotation tool for clinical genomic testing.
Liu Y et al.
Frontiers in Pharmacology, 2023
36778023 (PubMed )
Supplement: Table4.XLSX › DPYD
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.
Del Re M et al.
The Pharmacogenomics Journal, 2019
Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report.
Mukherji D et al.
Journal of Medical Case Reports, 2019
The Affymetrix DMET Plus platform reveals unique distribution of ADME-related variants in ethnic Arabs.
Wakil SM et al.
Disease Markers, 2015
25802476 (PubMed )
Supplement: 542543.f1.xlsx › DMET_Suppl_data
[Genetic polymorphisms related to fluoropyrimidine sensitivity and toxicity].
Terashima M
Gan to Kagaku Ryoho. Cancer & Chemotherapy, 2008
Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
Bosch TM
Methods in Molecular Biology (clifton, N.j.), 2008
Select a paper to view details